Overview

At Avalyn, patients are at the center of our business, and we strive to identify and implement patient feedback and meet the needs of the patient community we serve in every aspect of our work.

This is the right thing to do and will benefit both patients and Avalyn as we develop our medicines. We aim to deliver a positive clinical trial experience to research volunteers while advancing research efforts to provide improved therapeutic options.

Patients with ILDs (PPF & IPF) have few options and poor outcomes

Burden of IPF

Patient Info Graphic 1

Diagnosis + Treatment Delays

Patient Info Graphic 2

Tolerability Issues / Medicines

Patient Info Graphic 3

Outcomes

Patient Info Graphic 4
Sources:
– Lancaster et al. Respirology 2022 Jan;27(1):66-75.
– Chambers et al. J. Heart Lung Transplant, 2019, 38: 1042-1055
– Kistler et al. BMC Pulm Med, 2014, 14:139
– Takehara et al. Cells, 2022, 11:143
– Bellhassen et al. BMC Resp Res, 2021, 22:135
– Salisbury et al. Ann Am Thorac Soc. 2020 Nov;17(11):1413-1423.
– Holtze et al. Respir Res. 2020 Feb 10;21(1):48
– Kaunisto et al. ERJ Open Research 2019 5: 00170-2018

Patient Resources

Action for Pulmonary Fibrosis LogoAmerican Lung Association Patient Resources LogoAmerican Thoracic Society Patient Resources LogoERS Patient Resource LogoPulmonary Fibrosis Foundation Patient Resource Logo

Clinical Trials

Information Coming Soon